Natera (NASDAQ:NTRA) Stock: Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $414.22, for a total value of $1,242,660.00. Following the transaction, the insider directly owned 106,914 shares in the company, valued at $44,285,917.08. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total value of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total value of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $263,094.90.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $1.88 during midday trading on Friday, hitting $410.35. 2,156,324 shares of the company’s stock traded hands, compared to its average volume of 1,566,597. The firm has a fifty day moving average of $332.39 and a 200 day moving average of $261.01. Natera, Inc. has a 1 year low of $160.59 and a 1 year high of $427.47. The stock has a market capitalization of $59.15 billion, a price-to-earnings ratio of -301.73 and a beta of 1.50.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.74) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th. TD Cowen lifted their price objective on Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Piper Sandler boosted their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein began coverage on shares of Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price for the company. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $341.55.

Hedge Funds Weigh In On Natera

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Natera in the 2nd quarter worth approximately $2,962,770,000. JPMorgan Chase & Co. raised its position in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Castle Hook Partners LP lifted its holdings in shares of Natera by 24.1% in the fourth quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company’s stock worth $496,637,000 after buying an additional 420,621 shares in the last quarter. Capital World Investors boosted its position in shares of Natera by 1.4% during the fourth quarter. Capital World Investors now owns 1,433,094 shares of the medical research company’s stock worth $328,308,000 after acquiring an additional 20,371 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of Natera by 10.0% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,219,045 shares of the medical research company’s stock worth $279,271,000 after acquiring an additional 110,715 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.